Baumann 2011.
| Methods | Randomised controlled phase II trial | |
| Participants | 45 ovarian cancer patients with evidence of disease after first‐ or second‐line chemotherapy | |
| Interventions | Intraperitoneal trifunctional bispecific antibody (catumaxomab ‐ EpCAM): low dose (10‐10‐10‐10 μg) vs high dose (10‐20‐50‐100 μg) | |
| Outcomes | Tumour responses Survival (progression‐free survival/overall survival) Immune responses: humoral (HAMA) Adverse events |
|
| Notes | ||
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Low risk | Computer‐generated randomisation list |
| Allocation concealment (selection bias) | Unclear risk | Not explicitly stipulated |
| Blinding of participants and personnel (performance bias) All outcomes | High risk | Open‐label study |
| Blinding of outcome assessment (detection bias) All outcomes | Unclear risk | Data insufficient to permit judgement |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | Similar reasons for missing data across groups |
| Selective reporting (reporting bias) | Unclear risk | Study protocol not publicly available |
| Other bias | Low risk | No other sources of bias detected |